

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

NOVARTIS PHARMACEUTICALS
CORPORATION and NOVARTIS AG,

Plaintiffs,

v.

PAR PHARMACEUTICAL, INC.,

Defendant.

C.A. No. 14-1289-RGA

C.A. No. 14-1494-RGA

C.A. No. 15-0078-RGA

NOTICE OF APPEAL

Notice is hereby given that Plaintiffs Novartis Pharmaceuticals Corporation and Novartis AG appeal to the United States Court of Appeals for the Federal Circuit from the Final Judgment entered on May 16, 2017 in Civil Actions Nos. 14-1289-RGA (D.I. 180), 14-1494-RGA (D.I. 108) and 15-0078-RGA (D.I. 107) as it relates to the validity of U.S. Patent No. 5,665,772, and all underlying orders and findings made prior to, during, and after trial concerning U.S. Patent No. 5,665,772, including but not limited to the Amended Trial Opinion entered on April 3, 2017 in Civil Action No. 14-1289-RGA (D.I. 171).

Dated: June 14, 2017

McCARTER & ENGLISH, LLP

/s/ Daniel M. Silver

Daniel M. Silver (#4758)

Renaissance Centre

405 N. King Street, 8th Floor

Wilmington, Delaware 19801

(302) 984-6300

dsilver@mccarter.com

Attorneys for Plaintiffs

Of Counsel:

Nicholas N. Kallas
Christopher E. Loh
Charlotte Jacobsen
Christina Schwarz
FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, New York 10104-3800
(212) 218-2100
nkallas@fchs.com
cloh@fchs.com
cjacobsen@fchs.com
cschwarz@fchs.com